Shares of KKR (NYSE: KKR ) have been a tremendous performer over the past year, more than doubling, as its business continues to generate strong inflows and cash flow. The stock has surged even more over the past week in hopes of Over fifteen years of experience making contrarian bets based on my macro view and stock-specific turnaround stories to garner outsized returns with a favorable risk/reward profile. If you want me to cover a specific stock or have a question for an article, just let me know! Analys ...

As many of my followers have noticed it, I have been quite bullish on high quality BDCs over the past 12-16 months. One theoretical exception to this high-quality rule is FS KKR Capital (NYSE: FSK ), which has beenRoberts Berzins has over a decade of experience in the financial management helping top-tier corporates shape their financial strategies and execute large-scale financings. He has also made significant efforts to institutionalize REIT framework in Latvia to boost the liquidity of pan-Baltic capita ...

PHILADELPHIA and NEW YORK, Nov. 6, 2024 /PRNewswire/ -- FS KKR Capital Corp. (NYSE: FSK), or the Company, today announced its financial and operating results for the quarter ended September 30, 2024, and that its board of directors previously, on October 8, 2024, declared a fourth quarter 2024 distribution of $0.70 per share.Financial and Operating Highlights for the Quarter Ended September 30, 2024(1) Net investment income of $0.77 per share, compared to $0.77 per share for the quarter ended June 30, 2024 ...

Financial Performance - Total revenues for Q3 2024 reached $4,791,696, a 44.5% increase from $3,315,481 in Q3 2023[25]. - Net income attributable to KKR & Co. Inc. common stockholders was $600,550 in Q3 2024, down 59.3% from $1,472,878 in Q3 2023[26]. - Comprehensive income attributable to KKR & Co. Inc. was $2,432,305 in Q3 2024, significantly higher than $559,909 in Q3 2023[28]. - The diluted earnings per share for Q3 2024 was $0.64, down from $1.64 in Q3 2023[26]. - Net income for the nine months ended September 30, 2024, was $3,521,754, a decrease of 6.5% compared to $3,767,726 in 2023[34]. Assets and Investments - Total assets increased to $360.66 billion as of September 30, 2024, up from $317.29 billion at December 31, 2023, representing a growth of approximately 13.6%[16]. - Total investments increased to $276.68 billion as of September 30, 2024, up from $240.01 billion on December 31, 2023, representing a growth of approximately 15.2%[88]. - Total investments in insurance increased to $172.38 billion from $141.37 billion, reflecting a growth of about 21.9%[16]. - Total cash, cash equivalents, and restricted cash at the end of the period was $14,962,439, up from $11,710,842 at the end of September 2023[35]. - The total balance of mortgage and other loan receivables was $621,244 as of September 30, 2024, slightly down from $602,443 at the end of the previous period[86]. Liabilities - Total liabilities grew to $298.86 billion as of September 30, 2024, compared to $258.92 billion at December 31, 2023, reflecting an increase of around 15.4%[17]. - The company reported accrued expenses and other liabilities in Asset Management and Strategic Holdings of $11.92 billion, up from $7.72 billion, representing a significant increase of about 54.5%[16]. - Total liabilities at fair value reached $33.76 billion as of September 30, 2024, compared to $30.15 billion on December 31, 2023, reflecting an increase of approximately 12.5%[165]. - Policy liabilities, including market risk benefits, were reported at $1.43 billion as of September 30, 2024, consistent with the previous reporting date[165]. Investment Income and Losses - The company reported net investment income of $1,701,826 for Q3 2024, compared to $1,412,130 in Q3 2023, an increase of 20.5%[25]. - The company experienced a net investment-related loss of $(235,971) in Q3 2024, compared to a loss of $(338,230) in Q3 2023[25]. - Total net gains from investment activities for the three months ended September 30, 2024, were $252,529, compared to $1,062,097 in 2023, showing a significant decrease[76]. - The company reported a net loss from private equity investments of $100,037 for the three months ended September 30, 2024, compared to a net gain of $75,764 in 2023[76]. Equity and Stockholder Information - Total stockholders' equity reached $60.48 billion, up from $57.76 billion, indicating an increase of approximately 3.0%[17]. - The company reported a common stock dividend of $155,306,000 for the three months ended September 30, 2024[30]. - The total equity of KKR & Co. Inc. stood at $60,476,302,000 as of September 30, 2024[30]. - The company’s retained earnings increased to $11,312,398,000 by the end of the reporting period[30]. Derivative Instruments and Hedging - The total notional value of derivatives was $84.5 billion, with derivative assets amounting to $86.1 million and derivative liabilities at $191.6 million[137]. - Total losses on derivatives designated as hedge instruments amounted to $91,222, with net policy benefits and claims at $55,641[149]. - The company reported total losses on derivatives not designated as hedge accounting instruments of $458,540, with embedded derivatives showing a loss of $1,305,338[149]. - The effectiveness of cash flow hedges is assessed using regression analysis, with expected earnings impact until 2054[141]. Accounting and Regulatory Compliance - KKR's financial statements are prepared in accordance with GAAP and include consolidated results from KKR Group Partnership and its entities, reflecting significant industry diversification due to the acquisition of Global Atlantic[48][49]. - The adoption of ASU 2022-03 regarding fair value measurement of equity securities did not have a material impact on KKR's consolidated financial statements[68]. - The company is currently evaluating the impact of new accounting standards on its consolidated financial statements and disclosures, including ASU 2023–07 and ASU 2023–09[71][73].

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure: I/we have a beneficial long position in the shares of FSK, ARCC, ...

FS KKR Capital (NYSE: FSK ), a business development company (BDC), has a sensitive portfolio position in the face of the (likely) proceeding interest rate decreases. However, there are a few aspects to consider when evaluating a BDC's capability to uphold dividend payments in a changing marketWelcome to Cash Flow Venue, where dividends do the heavy lifting! Blending my financial chops with the timeless wisdom of value investing (and love for steady income), I’ve built a rock-solid pillar in my financial fou ...

Leading global investment firms file for two public-private fixed income interval funds to launch in the U.S. in the first half of 2025, pending regulatory approval New category of public-private solutions to expand over time across multiple asset classes and geographies LOS ANGELES, Oct. 29, 2024 /PRNewswire/ -- Leading global investment firms Capital Group and KKR today filed registration statements with the SEC for two public-private fixed income funds, Capital Group KKR Core Plus+ and Capital Group KKR ...

Core Insights - Resolian is undergoing leadership changes to enhance its global operations and better support client needs [2][3] - The company has expanded its global footprint through strategic acquisitions and the establishment of new facilities [3][9] Leadership Changes - Rob Stachlewitz has been appointed as the new CEO, transitioning from his role at Charles River [5][6] - Pat Bennett, the former CEO, will take on the role of Chief Business Officer and President of Scientific Affairs [2][7] - Honggang Bi has been appointed as Chairman, bringing over 30 years of experience in drug development [4][6] Company Expansion - Resolian has made significant acquisitions, including Alliance Pharma, Drug Development Solutions, and Denali MedPharm, expanding its operations to four continents [3][9] - The establishment of a new bioanalytical lab in Brisbane, Australia, enhances its operational capabilities [3] Operational Focus - The leadership team aims to improve service capabilities and strengthen customer relationships [7][8] - The company employs nearly 500 experts across the U.S., U.K., and Australia, ensuring high standards of regulatory compliance [9]

The second largest alternative asset manager, KKR (NYSE: KKR ) , reported Q3 earnings on Thursday that came in better than expected. EPS was higher by 0.18 cents, consolidating the metric at $1.36 , which represents Hey there! My focus here is to provide you with insightful rating analysis on the world's leading financial firms to help you navigate and comprehend the latest investment opportunities while identifying potential pitfalls. My favorite picks are those that are tilted toward both the growth and q ...

KKR & Co. Inc. (NYSE:KKR) Q3 2024 Earnings Conference Call October 24, 2024 10:00 AM ET Company Participants Craig Larson - Partner and Head of IR Scott Nuttall - Co-Chief Executive Officer Rob Lewin - Chief Financial Officer Conference Call Participants Craig Siegenthaler - Bank of America Glenn Schorr - Evercore ISI Alexander Blostein - Goldman Sachs Bill Katz - TD Cowen Brian McKenna - Citizens JMP Steven Chubak - Wolfe Research Patrick Davitt - Autonomous Research Michael Brown - Wells Fargo Brian Bedel ...